Willow Biosciences Inc. announced a collaboration with Enterin, Inc. to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs). Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale.

The development phase of this funded collaboration is expected to last approximately three months. This agreement represents the 3rd development agreement with innovator/discovery food or pharma companies seeking access to Willow's transformative BioOxiTM selective hydroxylation platform.